

**COMMONWEALTH OF KENTUCKY  
CABINET FOR HEALTH AND FAMILY SERVICES  
DEPARTMENT FOR MEDICAID SERVICES  
PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE MEETING**

**NOTE: This special called meeting will be held virtually via Zoom webinar.**

Thursday, September 21, 2023

1:00 P.M. to 4:00 P.M. (Eastern)

**Access Information**

Smartphone/Web	Dial-In
<a href="https://magellanhealth.zoom.us/j/95532018515">https://magellanhealth.zoom.us/j/95532018515</a> Webinar ID: 955 3201 8515 Password: 963559	+1 312 626 6799 (US Toll) OR +1 646 558 8656 (US Toll) Webinar ID: 955 3201 8515 Password: 963559

**AGENDA**

- I. Call to Order and Welcome**
- II. Executive Session (upon request)**
- III. Old Business**
  - a. Approval of November 2022 Meeting Minutes
  - b. Approval of March 2023 Meeting Minutes
  - c. Approval of May 2023 Meeting Minutes
- IV. New Business**
  - a. New Products to Market to be reviewed as single products:
    - i. Abilify Asimtufii<sup>®</sup> (*Antipsychotics:Injectable*)
    - ii. Daybue<sup>™</sup> (*Non-PDL Drug*)
    - iii. Inpefa<sup>™</sup> (*Diabetes: SGLT2*)
    - iv. Sogrova<sup>®</sup> (*Growth Hormones*)
    - v. Uzedy (*Antipsychotics: Injectable*)
    - vi. Veozah<sup>™</sup> (*Non-PDL Drug*)
    - vii. Zavzpret<sup>™</sup> (*Anti-Migraine: CGRP Inhibitors*)
- V. Therapeutic Classes with Recommended Changes**
  - a. Angiotensin Modulator Combinations (Angiotensin Modulator + CCB Combinations)
  - b. Angiotensin Modulators (ACE Inhibitors)
  - c. Anticoagulants
  - d. Sedative Hypnotics
- VI. Consent Agenda**
  - a. The following therapeutic classes have no changes recommended and may be voted on as a group under a consent agenda:

<ul style="list-style-type: none"> <li>• Alzheimer's Agents</li> <li>• Angiotensin Modulators (Angiotensin Receptor Blockers, Direct Renin Inhibitors)</li> <li>• Angiotensin Modulators Combinations (ACEI + Diuretic Combinations, ARB + Diuretic Combinations)</li> <li>• Antianginal &amp; Anti-Ischemic</li> <li>• Antiarrhythmics, Oral</li> <li>• Anticonvulsants (Anticonvulsants: First Generation, Anticonvulsants: Second Generation, Anticonvulsants: Carbamazepine Derivatives)</li> <li>• Antidepressants, Other (Antidepressants: Other, Antidepressants: MAOIs, Antidepressants, SNRI)</li> <li>• Antidepressants, SSRI</li> <li>• Antidepressants, Tricyclics</li> <li>• Antimigraine Agents, Other (Anti-Migraine: CGRP Inhibitors)</li> <li>• Antiparkinson's Agents (Dopamine Receptor Agonists, Parkinson's Disease)</li> </ul>	<ul style="list-style-type: none"> <li>• Antipsychotics [First-Generation (oral), Second-Generation (oral), Antipsychotics: Injectable]</li> <li>• Anxiolytics</li> <li>• Beta-Blockers (Alpha/Beta Blockers, Beta Blockers + Diuretic Combinations)</li> <li>• Bladder Relaxant Preparations</li> <li>• BPH Treatments</li> <li>• Calcium Channel Blockers (DHP, Non-DHP)</li> <li>• Lipotropics, Other (Lipotropics: Bile Acid Sequestrant, Lipotropics: Fibric Acid Derivatives, Lipotropics: Other)</li> <li>• Lipotropics, Statins</li> <li>• Movement Disorders</li> <li>• Narcolepsy Agents</li> <li>• Platelet Aggregation Inhibitors</li> <li>• Pulmonary Arterial Hypertension (PAH) Agents, Oral and Inhaled</li> <li>• Stimulants and Related Agents</li> <li>• Smoking Cessation (Tobacco Cessation)</li> </ul>
--	--

## VII. Adjournment

### a. Schedule of Upcoming Meetings

#### i. November 16, 2023

To view the most current Preferred Drug List (PDL) and Prior Authorization (PA) criteria please go to <https://kyportal.magellanmedicaid.com/provider/public/home.xhtml>.

**PUBLIC SPEAKERS:** If you would like to speak during the public session, please complete the Speaker Request Form located on the Committees/P&T tab of the Kentucky specific Magellan Medicaid Administration web portal at:

<https://kyportal.magellanmedicaid.com/provider/public/documents.xhtml>.